Synthesis and biological evaluation of aminobenzamides containing purine moiety as class I histone deacetylases inhibitors
Authors:
- 1 February 2022
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 56, 116599
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (81360469, 81860610)
This publication has 61 references indexed in Scilit:
- The histone deacetylase inhibitor entinostat (SNDX-275) induces apoptosis in Hodgkin lymphoma cells and synergizes with Bcl-2 family inhibitorsExperimental Hematology, 2011
- Chemical phylogenetics of histone deacetylasesNature Chemical Biology, 2010
- HDAC expression and clinical prognosis in human malignanciesCancer Letters, 2009
- AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibilityJournal of Computational Chemistry, 2009
- Pimelic Diphenylamide 106 Is a Slow, Tight-binding Inhibitor of Class I Histone DeacetylasesJournal of Biological Chemistry, 2008
- Evaluation of the Pharmacodynamic Effects of MGCD0103 from Preclinical Models to Human Using a Novel HDAC Enzyme AssayClinical Cancer Research, 2008
- MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivoMolecular Cancer Therapeutics, 2008
- Anticancer activities of histone deacetylase inhibitorsNature Reviews Drug Discovery, 2006
- UCSF Chimera—A visualization system for exploratory research and analysisJournal of Computational Chemistry, 2004
- Upregulation and Nuclear Recruitment of HDAC1 in Hormone Refractory Prostate CancerThe Prostate, 2004